• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在哥伦比亚新冠疫情的四个流行高峰期间，灭活全病毒疫苗和基因疫苗引发的针对主要新冠病毒变异株的中和抗体反应

Neutralizing Antibody Responses Elicited by Inactivated Whole Virus and Genetic Vaccines against Dominant SARS-CoV-2 Variants during the Four Epidemic Peaks of COVID-19 in Colombia.

作者信息

Álvarez-Díaz Diego A, Muñoz Ana Luisa, Herrera-Sepúlveda María T, Tavera-Rodríguez Pilar, Laiton-Donato Katherine, Franco-Muñoz Carlos, Ruiz-Moreno Héctor Alejandro, Galindo Marisol, Catama Jenssy D, Bermudez-Forero Andrea, Mercado-Reyes Marcela

机构信息

Genómica de Microorganismos Emergentes, Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá 111321, Colombia.

Facultad de Ciencias Biología, Universidad Nacional de Colombia, Bogotá 111321, Colombia.

出版信息

Vaccines (Basel). 2022 Dec 14;10(12):2144. doi: 10.3390/vaccines10122144.

DOI:10.3390/vaccines10122144
PMID:36560554
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9786731/
Abstract

Several SARS-CoV-2 variants of concern (VOC) and interest (VOI) co-circulate in Colombia, and determining the neutralizing antibody (nAb) responses is useful to improve the efficacy of COVID-19 vaccination programs. Thus, nAb responses against SARS-CoV-2 isolates from the lineages B.1.111, P.1 (Gamma), B.1.621 (Mu), AY.25.1 (Delta), and BA.1 (Omicron), were evaluated in serum samples from immunologically naïve individuals between 9 and 13 weeks after receiving complete regimens of CoronaVac, BNT162b2, ChAdOx1, or Ad26.COV2.S, using microneutralization assays. An overall reduction of the nAb responses against Mu, Delta, and Omicron, relative to B.1.111 and Gamma was observed in sera from vaccinated individuals with BNT162b2, ChAdOx1, and Ad26.COV2.S. The seropositivity rate elicited by all the vaccines against B.1.111 and Gamma was 100%, while for Mu, Delta, and Omicron ranged between 32 to 87%, 65 to 96%, and 41 to 96%, respectively, depending on the vaccine tested. The significant reductions in the nAb responses against the last three dominant SARS-CoV-2 lineages in Colombia indicate that booster doses should be administered following complete vaccination schemes to increase the nAb titers against emerging SARS-CoV-2 lineages.

摘要

几种值得关注的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变异株（VOC）和感兴趣的变异株（VOI）在哥伦比亚共同传播，确定中和抗体（nAb）反应有助于提高新冠疫苗接种计划的效果。因此，使用微量中和试验，对接受科兴疫苗、BNT162b2、ChAdOx1或Ad26.COV2.S完整接种方案9至13周后免疫初免个体的血清样本中针对B.1.111、P.1（伽马）、B.1.621（缪）、AY.25.1（德尔塔）和BA.1（奥密克戎）谱系的SARS-CoV-2分离株的nAb反应进行了评估。在接种BNT162b2、ChAdOx1和Ad26.COV2.S的个体血清中，相对于B.1.111和伽马变异株，观察到针对缪、德尔塔和奥密克戎变异株的nAb反应总体降低。所有疫苗针对B.1.111和伽马变异株的血清阳性率均为100%，而针对缪、德尔塔和奥密克戎变异株的血清阳性率分别在32%至87%、65%至96%和41%至96%之间，具体取决于所测试的疫苗。针对哥伦比亚最后三种主要SARS-CoV-2谱系的nAb反应显著降低，这表明在完成疫苗接种方案后应接种加强针，以提高针对新出现的SARS-CoV-2谱系的nAb滴度。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c25/9786731/559cc5496415/vaccines-10-02144-g002a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c25/9786731/df3c3851bdaf/vaccines-10-02144-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c25/9786731/559cc5496415/vaccines-10-02144-g002a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c25/9786731/df3c3851bdaf/vaccines-10-02144-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c25/9786731/559cc5496415/vaccines-10-02144-g002a.jpg

相似文献

1
Neutralizing Antibody Responses Elicited by Inactivated Whole Virus and Genetic Vaccines against Dominant SARS-CoV-2 Variants during the Four Epidemic Peaks of COVID-19 in Colombia.在哥伦比亚新冠疫情的四个流行高峰期间，灭活全病毒疫苗和基因疫苗引发的针对主要新冠病毒变异株的中和抗体反应
Vaccines (Basel). 2022 Dec 14;10(12):2144. doi: 10.3390/vaccines10122144.
2
Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2.在未免疫的仓鼠中使用Ad26.COV2.S或奥密克戎适应疫苗进行加强免疫可预防奥密克戎BA.2。
NPJ Vaccines. 2023 Mar 16;8(1):40. doi: 10.1038/s41541-023-00633-x.
3
Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine.在先前接种科兴疫苗的老年人中，接种ChAdOx-1或BNT162b2加强针后针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变异株的中和抗体及T细胞反应
Immun Ageing. 2022 May 24;19(1):24. doi: 10.1186/s12979-022-00279-8.
4
Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines.加强剂对康复的 COVID-19 患者血清中和针对奥密克戎变异株的活性：BNT162b2 和科兴疫苗的效果。
EBioMedicine. 2022 May;79:103986. doi: 10.1016/j.ebiom.2022.103986. Epub 2022 Apr 8.
5
CoronaVac-vaccinated kidney transplant recipients with hybrid immunity have strong neutralizing responses against Omicron and Mu variants of SARS-CoV-2.具有混合免疫的科兴疫苗接种肾移植受者对新冠病毒奥密克戎和缪毒株具有强烈的中和反应。
Braz J Microbiol. 2024 Dec;55(4):3303-3308. doi: 10.1007/s42770-024-01507-7. Epub 2024 Sep 10.
6
Comparison of Immunogenicity and Reactogenicity of Five Primary Series of COVID-19 Vaccine Regimens against Circulating SARS-CoV-2 Variants of Concern among Healthy Thai Populations.泰国健康人群中五种主要系列新冠疫苗接种方案针对正在传播的新冠病毒变异株的免疫原性和反应原性比较
Vaccines (Basel). 2023 Mar 1;11(3):564. doi: 10.3390/vaccines11030564.
7
Equal Maintenance of Anti-SARS-CoV-2 Antibody Levels Induced by Heterologous and Homologous Regimens of the BNT162b2, ChAdOx1, CoronaVac and Ad26.COV2.S Vaccines: A Longitudinal Study Up to the 4th Dose of Booster.BNT162b2、ChAdOx1、CoronaVac和Ad26.COV2.S疫苗的异源和同源接种方案诱导的抗SARS-CoV-2抗体水平的同等维持：一项直至第四剂加强针的纵向研究
Vaccines (Basel). 2024 Jul 18;12(7):792. doi: 10.3390/vaccines12070792.
8
Levels and durability of neutralizing antibodies against SARS-CoV-2 Omicron and other variants after ChAdOx-1 or BNT162b2 booster in CoronaVac-primed elderly individuals.在科兴疫苗初免的老年个体中，接种ChAdOx-1或BNT162b2加强针后针对新冠病毒奥密克戎及其他变体的中和抗体水平和持久性。
Heliyon. 2023 Apr;9(4):e15653. doi: 10.1016/j.heliyon.2023.e15653. Epub 2023 Apr 20.
9
Comparison of BNT162b2-, mRNA-1273- and Ad26.COV2.S-Elicited IgG and Neutralizing Titers against SARS-CoV-2 and Its Variants.BNT162b2、mRNA-1273和Ad26.COV2.S诱导的针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）及其变体的IgG和中和抗体滴度的比较
Vaccines (Basel). 2022 May 27;10(6):858. doi: 10.3390/vaccines10060858.
10
Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccines.新冠疫苗初免和加强剂量接种后针对新冠病毒变异株的疫苗诱导抗体中和作用比较
Front Med (Lausanne). 2022 Oct 3;9:994160. doi: 10.3389/fmed.2022.994160. eCollection 2022.

引用本文的文献

1
Immunogenicity of the CoronaVac vaccine in children: a real-world study.科兴新冠疫苗在儿童中的免疫原性：一项真实世界研究。
Front Immunol. 2024 Dec 23;15:1504935. doi: 10.3389/fimmu.2024.1504935. eCollection 2024.
2
CoronaVac-vaccinated kidney transplant recipients with hybrid immunity have strong neutralizing responses against Omicron and Mu variants of SARS-CoV-2.具有混合免疫的科兴疫苗接种肾移植受者对新冠病毒奥密克戎和缪毒株具有强烈的中和反应。
Braz J Microbiol. 2024 Dec;55(4):3303-3308. doi: 10.1007/s42770-024-01507-7. Epub 2024 Sep 10.
3
Cross-reactive humoral and CD4 T cell responses to Mu and Gamma SARS-CoV-2 variants in a Colombian population.

本文引用的文献

1
Comparison of Anti-SARS-CoV-2 IgG Antibody Responses Generated by the Administration of Ad26.COV2.S, AZD1222, BNT162b2, or CoronaVac: Longitudinal Prospective Cohort Study in the Colombian Population, 2021/2022.Ad26.COV2.S、AZD1222、BNT162b2或科兴新冠疫苗接种后产生的抗SARS-CoV-2 IgG抗体反应比较：2021/2022年哥伦比亚人群纵向前瞻性队列研究
Vaccines (Basel). 2022 Sep 26;10(10):1609. doi: 10.3390/vaccines10101609.
2
SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic.COVID-19 大流行不断变化的格局中的 SARS-CoV-2 特异性 T 细胞。
Immunity. 2022 Oct 11;55(10):1764-1778. doi: 10.1016/j.immuni.2022.08.008. Epub 2022 Aug 18.
3
哥伦比亚人群中对 Mu 和 Gamma SARS-CoV-2 变体的交叉反应性体液和 CD4 T 细胞应答。
Front Immunol. 2023 Jul 27;14:1241038. doi: 10.3389/fimmu.2023.1241038. eCollection 2023.
4
Intensive Care during the COVID-19 Pandemic.新冠疫情期间的重症监护
Vaccines (Basel). 2023 Jan 4;11(1):125. doi: 10.3390/vaccines11010125.
Humoral Response to BNT162b2 Vaccine Against SARS-CoV-2 Variants Decays After Six Months.
体液免疫对 BNT162b2 疫苗针对 SARS-CoV-2 变异体的反应在六个月后下降。
Front Immunol. 2022 May 2;13:879036. doi: 10.3389/fimmu.2022.879036. eCollection 2022.
4
Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies multiple inter-variant recombination events.追踪 SARS-CoV-2 奥密克戎多样化的刺突基因突变，鉴定出多个变异株间重组事件。
Signal Transduct Target Ther. 2022 Apr 26;7(1):138. doi: 10.1038/s41392-022-00992-2.
5
Research progress on vaccine efficacy against SARS-CoV-2 variants of concern.关于针对 SARS-CoV-2 关切变异株疫苗效力的研究进展。
Hum Vaccin Immunother. 2022 Nov 30;18(5):2057161. doi: 10.1080/21645515.2022.2057161. Epub 2022 Apr 19.
6
The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines.不断演变的 SARS-CoV-2 突变和变体对 COVID-19 疫苗的影响。
mBio. 2022 Apr 26;13(2):e0297921. doi: 10.1128/mbio.02979-21. Epub 2022 Mar 30.
7
Evasion of vaccine-induced humoral immunity by emerging sub-variants of SARS-CoV-2.新兴 SARS-CoV-2 亚变种逃避疫苗诱导的体液免疫。
Future Microbiol. 2022 Apr;17:417-424. doi: 10.2217/fmb-2022-0025. Epub 2022 Mar 30.
8
Mutations and Evolution of the SARS-CoV-2 Spike Protein.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白的突变与进化
Viruses. 2022 Mar 19;14(3):640. doi: 10.3390/v14030640.
9
Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants.严重急性呼吸综合征冠状病毒2型奥密克戎BA.1和BA.2变体的中和作用
N Engl J Med. 2022 Apr 21;386(16):1579-1580. doi: 10.1056/NEJMc2201849. Epub 2022 Mar 16.
10
SARS-CoV-2 variants and spike mutations involved in second wave of COVID-19 pandemic in India.印度第二波 COVID-19 大流行中涉及的 SARS-CoV-2 变体和刺突突变。
Transbound Emerg Dis. 2022 Sep;69(5):e1721-e1733. doi: 10.1111/tbed.14508. Epub 2022 Mar 24.